ImmunoMet Therapeutics
PrivateLast Round
Series C
Oct 19, 2022
Total Funding Raised
$41.8M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ImmunoMet Therapeutics is a clinical-stage biotechnology company developing novel anti-cancer and anti-fibrotic therapies by targeting cellular metabolism.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoMet Therapeutics Comparables
Compare ImmunoMet Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Dracen Pharmaceuticals, Inc. | 77% | |
| Cornerstone Pharmaceuticals, Inc. | 75% | |
| One-carbon Therapeutics AB | 73% | |
ImmunoMet Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 19, 2022 | ||||
| Series B Extension | Dec 31, 2021 | ||||
| VC Round | Feb 8, 2021 | ||||
| Series B Extension | Feb 5, 2020 | ||||
| Convertible Debt | May 16, 2018 | ||||
Series B | Mar 7, 2017 |
Key People
Founding team and executive leadership
ImmunoMet Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| InterVest | Series B |
| SL Investment | Series B |
| NHN Investment | Series B |
| Mirae Asset Venture Investments | Series B, Series A |
| Mirae Asset Venture Investment | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 17, 2026
Monthly visitors grew 32% MoM, reaching 1.3K.
- Oct 19, 2022
Raised $8M in Series C funding.
ImmunoMet Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImmunoMet Therapeutics's valuation, stock price, and market status.